Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk

Dow Jones

10/20

0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 20, 2025 04:04 ET (08:04 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576836064"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576836064\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576836064?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576836064","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-10-20 16:04</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心資產","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576836064","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576836064","pubTimestamp":1760947440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"翰森制药与罗氏的交易可能有助于释放商业潜力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 04:04 ET (08:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}